<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156738</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2990-E01</org_study_id>
    <nct_id>NCT03156738</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of MT-2990 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and
      immunogenicity of MT-2990 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">December 29, 2017</completion_date>
  <primary_completion_date type="Actual">December 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by incidence, nature and severity of adverse events</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Adverse events will be summarised by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by vital signs</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Vital signs variables and changes from Baseline will be summarised by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by ECG parameters</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>12-lead ECG variables and changes from Baseline will be summarised by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by clinical laboratory assessments</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Laboratory variables and changes from Baseline will be summarised by dose level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as measured by physical examination</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Physical examination data will be listed by subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Cmax will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured time of maximum observed serum concentration (tmax) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>tmax will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>t½ will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to the last measurable concentration (AUC0-last) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>AUC0-last will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to infinity (AUC0-∞) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>AUC0-∞ will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Kel will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Vss will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase after IV administration (Vz) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Vz will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time from time zero to infinity (MRT0-∞) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>MRT0-∞ will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent serum clearance (CL) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>CL will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC obtained by extrapolation (%AUCex) of MT-2990</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>%AUCex will be summarised by dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who develop antibodies against MT-2990 in serum</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>The proportion of subjects who develop antibodies against MT 2990 in serum will be summarised using descriptive statistics on the Safety Analysis Set.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-2990 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-2990 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-2990 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-2990 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-2990 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-2990</intervention_name>
    <description>Subjects will receive a single IV dose of MT-2990</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive a single IV dose of placebo</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are able and willing to provide written informed consent to participate in
             this study

          -  Healthy male subjects aged 18 to 55 years (inclusive)

          -  Free from clinically significant (CS) illness or disease

          -  Body weight of 60 to 100 kg (inclusive)

          -  Body mass index (Quetelet index) ranging from 18 to 30 kg/m2 (inclusive).

        Exclusion Criteria:

          -  A CS endocrine, thyroid, hepatic, respiratory, gastrointestinal, neurological
             (including history of seizures), renal, cardiovascular disease, or history of any
             significant psychiatric/psychotic illness or disorder (including anxiety, depression
             and reactive depression)

          -  Presence or history of any known malignancy with the exception of basal cell carcinoma
             in situ of the skin that has been treated with no evidence of recurrence within 6
             months prior to the Screening Visit

          -  A history of bacterial or viral infections that led to hospitalisation and IV
             antibiotic or antiviral treatment within 3 months prior to Screening, or any recent
             infection requiring antibiotic or antiviral treatment within 4 weeks of Day -1

          -  A history of recurrent or chronic sinusitis, bronchitis, pneumonia, urinary tract
             infection (recurrent or chronic infection is two episodes within 6 months)

          -  A history of tuberculosis (TB) or malaria; history or any evidence of active infection
             or febrile illness within 7 days of dosing (e.g., bronchopulmonary, urinary, or
             gastrointestinal)

          -  An active, or history of, parasitic infections; any history of known or suspected
             congenital or acquired immunodeficiency state or condition that would compromise the
             subject's immune status (e.g., history of splenectomy)

          -  Presence or history of severe adverse reaction or allergy to any drug or allergy that
             is of clinical significance to the Investigational Medicinal Product (IMP)

          -  A positive test result for QuantiFERON-TB Gold® Plus, hepatitis B surface antigen,
             hepatitis B core antibody, hepatitis C antibody, or human immunodeficiency virus
             (HIV)-1 or HIV-2 antibodies at Screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates (PRA) Health Sciences</name>
      <address>
        <city>NZ Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

